Circassia Group PLC

("Circassia" or the "Company")

Proposed Change of Name
and
Notice of General Meeting

Circassia Group PLC, (AIM: CIR), a company engaged in the design, development and commercialisation of medical devices for asthma diagnosis and management, announces that the Company intends to change its name to Niox Group plc.

The directors believe that the change of name will more closely align its corporate identity and growth strategy with the identity of its principal market leading product, NIOX VERO.

The proposed change of name, in order to take effect, requires shareholders to pass a special resolution at a general meeting of the Company. A circular was sent to shareholders on 10 August 2022 to convene a general meeting of shareholders on 1 September 2022 (the "General Meeting") in order for them to vote on the Company's proposed change of name. The General Meeting will be held at 10.00 a.m. on 1 September 2022 at the Company's registered office: Hayakawa Building, Edmund Halley Road, Oxford Science Park, Oxford, OX4 4GB.The TIDM 'NIOX' has been reserved.

Full details on the implementation of the change of name, including any changes to the Group's website, and the effective date for the change of name and the TIDM will be announced after the General Meeting.

Contacts

Circassia

Ian Johnson, Executive Chairman                                                                   Tel: +44 (0) 1865 405 560

Michael Roller, Chief Financial Officer

Singer Capital Markets (Nominated Adviser and Broker)

Aubrey Powell/ Jen Boorer                                                                          Tel: +44 (0) 20 7496 3000

About Circassia

Our ambition is to improve the quality of life of millions of people suffering from asthma. The company is engaged in the design, development and commercialisation of medical devices for the diagnosis and management of asthma. Today our device, NIOX VERO, is used by healthcare professionals and leading research organisations. We passionately believe in empowering everyone to manage their health at home and are developing NIOX for home use to meet this need. At present, Circassia provides products and services in around 50 countries. For more information please visit www.circassia.com.